FDA is­sues sec­ond CRL to Su­per­nus for Parkin­son's drug-de­vice com­bo

It seems Su­per­nus Phar­ma­ceu­ti­cals will need a su­per ef­fort to get its Parkin­son’s treat­ment ap­proved.

The FDA re­ject­ed the com­pa­ny’s ther­a­py for a sec­ond time …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER